State Street SPDR S&P Pharmaceuticals ETF (XPH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
State Street SPDR S&P Pharmaceuticals ETF (XPH) with AI Score 47/100 (Weak). The State Street SPDR S&P Pharmaceuticals ETF (XPH) aims to replicate the performance of the S&P Pharmaceuticals Select Industry Index. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 17, 2026State Street SPDR S&P Pharmaceuticals ETF (XPH) Financial Services Profile
State Street SPDR S&P Pharmaceuticals ETF (XPH) provides targeted exposure to the pharmaceuticals segment of the S&P TMI, tracking a modified equal-weighted index. This ETF allows investors to strategically position themselves within the pharmaceutical industry, offering diversified exposure across large, mid, and small-cap stocks.
Investment Thesis
The State Street SPDR S&P Pharmaceuticals ETF (XPH), with a market capitalization of $0.22 billion and a beta of 0.89, offers a targeted investment in the pharmaceutical sector. The ETF's modified equal-weighted approach provides diversification across large, mid, and small-cap pharmaceutical companies. A key value driver is the potential for growth in the pharmaceutical industry, driven by factors such as aging populations, increasing healthcare spending, and advancements in drug development. Upcoming catalysts include potential breakthroughs in pharmaceutical research and development, regulatory approvals for new drugs, and expansion into emerging markets. Potential risks include regulatory changes, patent expirations, and increased competition from generic drug manufacturers. While the ETF does not offer a dividend yield, its potential for capital appreciation makes it a noteworthy option for investors seeking exposure to the pharmaceutical sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.22 billion, indicating a relatively small ETF focused on a specific sector.
- Beta of 0.89 suggests the ETF is slightly less volatile than the broader market.
- The ETF tracks the S&P Pharmaceuticals Select Industry Index, providing targeted exposure to the pharmaceutical sector.
- Modified equal-weighted index aims to provide diversification across large, mid, and small-cap stocks within the pharmaceutical industry.
- Absence of dividend yield may appeal to growth-oriented investors rather than income-seeking investors.
Competitors & Peers
Strengths
- Targeted exposure to the pharmaceutical sector.
- Diversification across large, mid, and small-cap stocks.
- Modified equal-weighted index methodology.
- Low expense ratio.
Weaknesses
- Sector-specific focus may lead to higher volatility.
- Lack of dividend yield may not appeal to all investors.
- Performance is tied to the performance of the S&P Pharmaceuticals Select Industry Index.
Catalysts
- Upcoming: Regulatory approvals for new drugs and therapies.
- Ongoing: Advancements in pharmaceutical research and development.
- Ongoing: Expansion of pharmaceutical companies into emerging markets.
- Ongoing: Increasing healthcare spending globally.
Risks
- Potential: Regulatory changes and patent expirations.
- Potential: Increased competition from generic drug manufacturers.
- Potential: Economic downturns that could reduce healthcare spending.
- Ongoing: Sector-specific focus may lead to higher volatility.
- Ongoing: Dependence on the performance of the S&P Pharmaceuticals Select Industry Index.
Growth Opportunities
- Expanding into emerging markets: The pharmaceutical industry is experiencing significant growth in emerging markets due to increasing healthcare access and rising incomes. XPH can capitalize on this trend by increasing its exposure to pharmaceutical companies that are expanding their operations in these regions. This expansion could lead to higher returns for the ETF as these companies benefit from the growing demand for pharmaceuticals in emerging markets. The timeline for this growth opportunity is ongoing, as emerging markets continue to develop and their healthcare systems evolve.
- Capitalizing on advancements in drug development: The pharmaceutical industry is constantly innovating, with new drugs and therapies being developed to treat a wide range of diseases. XPH can benefit from these advancements by investing in pharmaceutical companies that are at the forefront of drug development. This includes companies that are developing novel therapies for diseases such as cancer, Alzheimer's disease, and diabetes. The timeline for this growth opportunity is ongoing, as pharmaceutical companies continue to invest in research and development.
- Benefiting from regulatory approvals for new drugs: Regulatory approvals for new drugs can be a significant catalyst for growth in the pharmaceutical industry. XPH can benefit from these approvals by investing in pharmaceutical companies that have recently received regulatory approval for their drugs. This can lead to higher returns for the ETF as these companies see increased sales and profits from their newly approved drugs. The timeline for this growth opportunity is ongoing, as pharmaceutical companies continue to seek regulatory approval for their drugs.
- Increasing healthcare spending: Healthcare spending is increasing globally due to factors such as aging populations and rising incomes. This trend is benefiting the pharmaceutical industry, as demand for pharmaceuticals is increasing. XPH can capitalize on this trend by investing in pharmaceutical companies that are benefiting from increased healthcare spending. This can lead to higher returns for the ETF as these companies see increased sales and profits. The timeline for this growth opportunity is ongoing, as healthcare spending continues to rise.
- Focusing on personalized medicine: Personalized medicine, which involves tailoring medical treatment to the individual characteristics of each patient, is a growing trend in the pharmaceutical industry. XPH can benefit from this trend by investing in pharmaceutical companies that are developing personalized medicine therapies. This can lead to higher returns for the ETF as these companies see increased demand for their personalized medicine products. The timeline for this growth opportunity is ongoing, as pharmaceutical companies continue to invest in personalized medicine.
Opportunities
- Growth in the pharmaceutical industry due to aging populations and increasing healthcare spending.
- Advancements in drug development and personalized medicine.
- Expansion into emerging markets.
- Increased demand for ETFs as investment vehicles.
Threats
- Regulatory changes and patent expirations.
- Increased competition from generic drug manufacturers.
- Economic downturns that could reduce healthcare spending.
- Unforeseen events, such as pandemics, that could disrupt the pharmaceutical supply chain.
Competitive Advantages
- Established brand name and reputation of State Street.
- Low expense ratio compared to actively managed funds.
- Diversification benefits through exposure to a basket of pharmaceutical stocks.
About XPH
The State Street SPDR S&P Pharmaceuticals ETF (XPH) was created to mirror the investment results, before accounting for fees and expenses, of the S&P Pharmaceuticals Select Industry Index. This index represents the pharmaceuticals sub-industry within the broader S&P Total Market Index (TMI). By tracking a modified equal-weighted index, XPH aims to provide investors with a less concentrated exposure to the pharmaceutical sector, diversifying holdings across companies of varying market capitalizations, including large-cap, mid-cap, and small-cap stocks. The ETF's structure allows investors to implement strategic or tactical investment approaches with a more focused lens than traditional sector-based investing. XPH's methodology seeks to avoid over-reliance on any single company's performance, potentially mitigating risk and providing a more balanced representation of the pharmaceutical industry's overall performance. The fund's objective is to offer a convenient and cost-effective way for investors to gain exposure to a basket of pharmaceutical companies without directly purchasing individual stocks. State Street, a well-established financial institution, manages the ETF, leveraging its expertise in investment management and ETF administration to provide investors with a reliable and transparent investment vehicle. As of 2026, XPH continues to serve as a tool for investors seeking to fine-tune their sector allocations and capitalize on the growth potential within the pharmaceuticals industry.
What They Do
- Tracks the performance of the S&P Pharmaceuticals Select Industry Index.
- Provides exposure to the pharmaceuticals segment of the S&P TMI.
- Utilizes a modified equal-weighted index methodology.
- Offers diversification across large, mid, and small-cap pharmaceutical stocks.
- Allows investors to take strategic or tactical positions in the pharmaceutical sector.
- Provides a cost-effective way to invest in a basket of pharmaceutical companies.
- Offers transparency in its holdings and investment strategy.
Business Model
- Generates revenue through management fees charged to investors.
- Fees are based on a percentage of the ETF's assets under management (AUM).
- Aims to provide investment results that correspond to the performance of its benchmark index.
Industry Context
The State Street SPDR S&P Pharmaceuticals ETF (XPH) operates within the asset management industry, specifically focusing on providing exposure to the pharmaceutical sector. The pharmaceutical industry is driven by factors such as aging populations, increasing healthcare spending, and advancements in drug development. The competitive landscape includes other ETFs and mutual funds that also focus on the healthcare or pharmaceutical sectors. XPH differentiates itself through its modified equal-weighted approach, which aims to provide diversification across companies of varying market capitalizations.
Key Customers
- Retail investors seeking exposure to the pharmaceutical sector.
- Institutional investors looking for a cost-effective way to diversify their portfolios.
- Financial advisors seeking to provide their clients with targeted sector exposure.
Financials
Chart & Info
State Street SPDR S&P Pharmaceuticals ETF (XPH) stock price: Price data unavailable
Latest News
-
US and China clash over fentanyl and tariffs at global drugs meeting
reuters.com · Mar 9, 2026
-
Short Interest in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Increases By 21.1%
defenseworld.net · Mar 6, 2026
-
These 5 Undervalued ETFs Could Be Bargains Right Now
247wallst.com · Feb 26, 2026
-
XPH's 29% Run Looks Tempting, But The 5y Chart Is A Warning
247wallst.com · Feb 18, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XPH.
Price Targets
Wall Street price target analysis for XPH.
MoonshotScore
What does this score mean?
The MoonshotScore rates XPH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
US and China clash over fentanyl and tariffs at global drugs meeting
Short Interest in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Increases By 21.1%
These 5 Undervalued ETFs Could Be Bargains Right Now
XPH's 29% Run Looks Tempting, But The 5y Chart Is A Warning
Latest State Street SPDR S&P Pharmaceuticals ETF Analysis
Common Questions About XPH
What does State Street SPDR S&P Pharmaceuticals ETF do?
The State Street SPDR S&P Pharmaceuticals ETF (XPH) is designed to mirror the performance of the S&P Pharmaceuticals Select Industry Index. This means it invests in a basket of pharmaceutical companies included in that index, providing investors with targeted exposure to the pharmaceutical sector. The ETF uses a modified equal-weighted approach, aiming to diversify its holdings across companies of varying sizes, from large-cap to small-cap. By investing in XPH, investors can gain exposure to the potential growth and returns of the pharmaceutical industry without having to individually select and manage a portfolio of pharmaceutical stocks.
What do analysts say about XPH stock?
Analyst consensus on XPH is pending, as AI analysis is currently unavailable. Key valuation metrics to consider include the ETF's price-to-earnings ratio, price-to-book ratio, and dividend yield (currently none). Growth considerations include the potential for the pharmaceutical industry to benefit from factors such as aging populations, increasing healthcare spending, and advancements in drug development. Investors should also consider the risks associated with investing in a sector-specific ETF, such as regulatory changes and patent expirations.
What are the main risks for XPH?
The main risks for XPH include regulatory changes, such as changes to drug pricing policies or approval processes, which could negatively impact the profitability of pharmaceutical companies. Patent expirations can also pose a risk, as pharmaceutical companies may lose exclusivity on their drugs, leading to increased competition from generic drug manufacturers. Economic downturns could reduce healthcare spending, which could negatively impact the demand for pharmaceuticals. Additionally, the ETF's sector-specific focus may lead to higher volatility compared to a more diversified investment.
How does State Street SPDR S&P Pharmaceuticals ETF generate revenue in the financial services sector?
State Street SPDR S&P Pharmaceuticals ETF generates revenue primarily through management fees. These fees are calculated as a percentage of the ETF's assets under management (AUM). The ETF charges investors a small percentage of the total value of their investment each year to cover the costs of managing the fund, including research, trading, and administrative expenses. The more assets the ETF manages, the more revenue it generates for State Street. This revenue model is typical for ETFs and other investment funds in the financial services sector.
How is State Street SPDR S&P Pharmaceuticals ETF positioned against other healthcare ETFs?
State Street SPDR S&P Pharmaceuticals ETF distinguishes itself from broader healthcare ETFs by focusing exclusively on the pharmaceutical sub-sector. While other healthcare ETFs may include companies from biotechnology, medical devices, and healthcare services, XPH offers a more targeted approach. This focus allows investors to fine-tune their exposure to the specific dynamics and growth drivers of the pharmaceutical industry, such as drug development, regulatory approvals, and patent landscapes. However, this also means XPH is more susceptible to risks specific to the pharmaceutical industry compared to more diversified healthcare ETFs.
What are the key factors to evaluate for XPH?
State Street SPDR S&P Pharmaceuticals ETF (XPH) currently holds an AI score of 47/100, indicating low score. Key strength: Targeted exposure to the pharmaceutical sector.. Primary risk to monitor: Potential: Regulatory changes and patent expirations.. This is not financial advice.
How frequently does XPH data refresh on this page?
XPH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven XPH's recent stock price performance?
Recent price movement in State Street SPDR S&P Pharmaceuticals ETF (XPH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Targeted exposure to the pharmaceutical sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for XPH, limiting the depth of some insights.
- Competitor list may not be exhaustive.